STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online)
ISSN: 2349-1299 (Print)
Volume 14, Issue 3, 2024
September–December
DOI (Journal): 10.37591/RRJoP

Review RRJoP

Immunotherapy Advancements in Cancer Treatment

Divyashree Patil[1,*], Divyani Patil[1], Bhagyashri Patil[1], Amit Kumar Dhankani[2], Mansi Dhankani[2], Sunil Pawar[3]

Abstract

Immuno-oncology has been one of the more exciting developments in the field of cancer treatment since about a century ago, with William B. Coley's work in the late 19th century, which really gave the field its beginnings with "Coley's toxin." In an initial effort that proved unsuccessful, early immunotherapy approaches utilizing bacterial mixtures to induce immune responses against tumors laid some groundwork for this field. It wasn't until over a century later that the first discoveries of immune checkpoint inhibitors like CTLA-4 and PD-1 changed things. Such therapies increase immune responses against cancer cells by circumventing mechanisms that suppress immune activity. Another approach that is just coming into maturity includes CAR-T cell therapy, monoclonal antibodies, cytokines, and therapeutic vaccines, among many others, for exploiting the body's immune system in cancer therapy. Notwithstanding these developments, challenges persist in optimizing the delivery mechanisms and overcoming tumor immunosuppression in solid tumors. Against this backdrop, this abstract reflects on the evolution, mechanisms, and current challenges of immunotherapy in cancer treatment, underscoring its potential to be transformative and requiring continuous effort to enhance its efficacy and safety.

Keywords: Immuno-oncology, Coley's toxin, immune checkpoint inhibitors, CTLA-4, PD-1.

INTRODUCTION

Exploring the Fundamentals of Immunotherapy

The field of immuno-oncology has brought about substantial changes in the treatment of cancer patients. William B. Coley, who is now recognized as the founder of immunotherapy, made the first attempt to harness the immune system's ability to cure cancer in the late 1800s. As an orthopedic surgeon caring for patients with bone sarcomas, he saw that in certain cases, when serious wound infections occurred after surgery—a common occurrence in the days before aseptic technique —the unresected tumors would spontaneously recede. Beginning in 1891, Coley injected mixtures of live and inactivated bacteria, such as *Streptococcus pyogenes* and *Serratia marcescens*, into more than a thousand patients in an effort to cause sepsis and elicit strong immune and anticancer responses. His bacterial mixture became known as "Coley's toxin" and is the first example of active cancer immunotherapy that is known to exist. Coley achieved full and permanent remissions from a number of malignancies, including testicular carcinoma, lymphoma, and sarcoma. However, because they were unaware of Coley's toxin's mode of action and because doing so carried the risk of purposefully exposing cancer patients to hazardous bacteria, oncologists selected radiation

***Author for Correspondence**
Divyashree Patil
E-mail: divyashree2609@gmail.com

[1]Student, Department of Quality Assurance, Poojya Sane Guruji Vidya Prasarak Mandal's College of Pharmacy, Nandurbar, Maharastra, India.
[2]Assistant Professor, Department of Quality Assurance, Poojya Sane Guruji Vidya Prasarak Mandal's College of Pharmacy, Nandurbar, Maharastra, India.
[3]Principal, Poojya Sane Guruji Vidya Prasarak Mandal's College of Pharmacy, Nandurbar, Maharastra, India.

Received Date: August 03, 2024
Accepted Date: September 14, 2024
Published Date: October 19, 2024

Citation: Divyashree Patil, Divyani Patil, Bhagyashri Patil, Amit Kumar Dhankani, Mansi Dhankani, Sunil Pawar. Immunotherapy Advancements in Cancer Treatment. Research & Reviews: A Journal of Pharmacology. 2024; 14(3): 22–28p.

treatment and surgery as alternative conventional therapies early in the 20th century.

It would take over fifty years for a deeper comprehension of the primary mediators of sepsis to provide some insight into the ways in which Coley's toxin works. These mediators belong to the family of cytokines that also includes interleukins, chemokines, and interferons. Once again, there was a hurry to apply those new discoveries to cancer treatment. Doctors and researchers had modest success with this novel approach; high-dose interleukin 2 (IL-2) in metastatic renal cell carcinoma occasionally caused clinical remissions, while interferon in stages III and IV melanoma produced dubious responses. Those little successes were often counterbalanced by significant failures. Only a tiny, carefully chosen minority of cancer patients would benefit from these novel ways of delivery, such as pegylation, despite the fact that they would lessen some of the toxicities due to the erratic and unpredictable immune responses observed with those medicines.

A deeper comprehension of the immune surveillance process—which is how innate immune cells eradicate cancer cells-led to the next revolutionary wave in cancer immunotherapy. Drs. Allison and Honjo received the 2018 Nobel Prize in Physiology or Medicine in appreciation of their work finding T cell immunological checkpoints, such as CTLA-4 and PD-1, which aided in the development of immuno-oncology in its contemporary form. Maintaining a careful balance between autoimmunity and immune surveillance against invasive pathogens or aberrant cells is the vital role of such hardwired signals. By inhibiting certain T cell surface receptors, one can boost autoimmunity and mount an immune response against tumors, but doing so may also raise the risk of autoimmune reactions [1].

TYPES OF IMMUNOTHERAPIES

Immunotherapy is a revolutionary approach to treating diseases by harnessing the power of the body's immune system. Immunotherapy comes in a variety of forms; each intended to boost or stimulate the immune response in a unique way:

- *Checkpoint inhibitors:* By focusing on immune cell checkpoints that cancer cells exploit to avoid detection, these medications strengthen the body's defenses against cancer.
- *Monoclonal antibodies:* These are designed in a lab to attach to particular targets on immunological or cancer cells, designating them for the immune system's eradication. Proteins called cytokines control the immune system's reaction. They can be used to enhance the immune system's capacity to identify and eliminate cancerous cells.
- *CAR T-cell therapy:* Entails genetically altering a patient's T-cells so that, upon being reinfused into the patient, they are better able to identify and combat cancer cells.
- *Vaccinations:* Just as standard vaccinations prime the immune system to combat diseases, cancer vaccines aim to activate the immune system to identify and target cancer cells [2–4].

Each type of immunotherapy has its own mechanisms and targets, offering new hope and treatment options for various diseases, particularly cancer, autoimmune disorders, and infectious diseases [5].

CHECKPOINT INHIBITORS

ICIs are cancer immunotherapies that increase the body's defenses against cancer by focusing on immunologic receptors found on T-lymphocyte surfaces. With the approval of ipilimumab in 2011, ICIs were therefore regarded as a breakthrough therapy option, transforming the management of cancer. In some situations, these drugs provided long-lasting effects with a reduced toxicity profile. ICIs function by reviving the host immune system to combat tumor cells, as opposed to conventional therapeutic approaches. In homeostatic settings, immune checkpoints regulate the ratio of pro-to-anti-inflammatory signals. These pathways, which are both stimulatory and inhibitory, affect the function of immune cells and are referred to as immunological checkpoints. The most often employed immunotherapeutic drugs within the past ten years have been antibodies that target immune inhibitory receptors, including CTLA-4, PD-1, and PD-L. Clinical development is underway for a number of

antibodies and small molecules that target different immune checkpoint proteins, such as CD39, CD73, the adenosine A2A receptor, B7H3, and CD47 (Figure 1).



Figure 1. Mechanism of action of checkpoint inhibitors [3].

Recent studies have identified a large number of novel immune checkpoint targets, such as T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig suppressor of T cell activation (VISTA), and T cell immunoglobulin and ITIM domain (TIGIT). According to this research, inhibiting one immune checkpoint may trigger an increase in the activity of other TME checkpoint receptors. It was discovered that TIM-3 and PD-1 had similar compensatory mechanisms in lung cancer [2].

CAR-T Cell Therapy

Treatment with chimeric antigen receptor (CAR)-T cells has been revolutionary because of the extraordinarily potent and long-lasting therapeutic responses it has generated. CARs are artificially created receptors that work to reroute lymphocytes, usually T cells, so they can identify and destroy cells that express a particular target antigen. Strong anti-tumor responses and strong T cell activation are the outcomes of CAR binding, which occurs independently of the MHC receptor, to target antigens produced on the cell surface.



Figure 2. Mechanism of action of CAR-T cell therapy [6].

Anti-CD19 CAR-T cell therapy was approved by the US Food and Drug Administration (FDA) in 2017 due to its remarkable effectiveness against B-cell malignancies. Some of the major issues with CAR-T cell therapy that still need to be addressed are the potentially fatal toxicities associated with the therapy, the limited effectiveness against solid tumors, the inhibition and resistance in B cell malignancies, antigen escape, limited persistence, poor trafficking and tumor infiltration, and the immunosuppressive microenvironment. The workforce must also change to meet the demands of this expanding and changing industry by creating educational programs that will prepare workers. Numerous ways have been put forth to increase anti-tumor activity, increase therapeutic efficacy, and reduce toxicities associated with CAR-T cell therapy. These tactics may involve combining the treatment with other anticancer medicines or utilizing novel CAR engineering techniques (Figure 2).

We address recent advancements in CAR-T cell engineering in this review, which aim to enhance clinical efficacy in solid tumors and hematological malignancies alike. We also discuss methods to get around existing obstacles, such as antigen escape, CAR-T cell trafficking, tumor infiltration, the immunosuppressive microenvironment, and toxicities associated with CAR-T cells [4].

Therapeutic Vaccines

The principal cause of death, malignant tumors, must be defeated if life expectancy is to rise globally. The severity of this challenge is shown by the startling projection of 19.3 million new instances of cancer and the regrettable toll of almost 10 million cancer-related deaths that were seen in 2020. It is urgent to create more effective cancer treatment methods because conventional cancer medicines, such as surgery, radiation therapy, and chemotherapy, are very hazardous and have limited use. According to recent relevant studies, “cancer immunoediting” appears to have a strong correlation with cancer progression. This dynamic interplay suggests that either by identifying altered oncogenic genes or by creating an immunosuppressive milieu that promotes tumor growth, the immune system can eliminate early cancer cells. Thus, a fine equilibrium within the immune system governs the fate of cancer cells.



Figure 3. Mechanism of action of cancer vaccines.

In the battle against cancer, immunotherapy has recently assumed a leading role. Numerous cutting-edge immunotherapies have been approved for clinical use, such as chimeric antigen receptor-T cell treatments, oncolytic viruses, and immune checkpoint inhibitors (ICIs). ICIs have been the most promising type of immunotherapy since the Food and Drug Administration (FDA) first approved the cytotoxic T-lymphocyte-associated antigen 4 antibody in 2011.Based on Haslam's research, 12% of cancer patients benefit from treatment, even though 43% of them match the criteria for using ICIs.

Thus, there is growing interest in investigating novel immunotherapeutic strategies to address this problem, such as therapeutic cancer vaccines. Originally, the main goal of vaccine development was to prevent infectious diseases (Figure 3).

However, their ability to amplify immune responses specific to antigens has been acknowledged as a potentially useful therapeutic tool in the fight against cancer. This study focuses on predefined cancer vaccines, which include shared antigens or individualized neoantigens; however, vaccines can contain unknown or preset antigens. After vaccination, antigen-presenting cells (APCs) take up the cancer antigen and convert antigens relevant to tumors into major histocompatibility complex (MHC) I/II complexes. The activated APCs then migrate into the lymph nodes that drain, where MHC I/II complexes attach to T lymphocytes, priming and activating them. Traveling in the direction of the tumor, the activated T cells are led by chemokine gradients and enter the tumor tissue under propitious co-stimulatory conditions. These activated T cells can directly destroy tumor cells and use cytokine-mediated mechanisms to regulate tumor growth once they are inside the tumor microenvironment [7].

Adoptive Cell Transfer

The most successful course of treatment for patients with metastatic melanoma is now adoptive cell therapy, or ACT. The earliest description of ACT-based immunotherapy dates to 1988 [1], but the advent of an immunodepleting preparative regimen prior to adoptive transfer in 2002 marked a significant improvement in efficacy. This regimen had the potential to clonally repopulate patients with anti-tumor T cells. 50% of patients with metastatic melanoma that are unresponsive to prior treatments will show an objective response, and a few may show a complete response. The brain is one organ location that can exhibit long-lasting responses. Enhancing and expanding the use of the ACT strategy for patients with a broad range of cancer types has become possible with the recent discoveries showing that normal human cells can be genetically modified to detect cancer antigens and mediate cancer regression in vivo. These papers offer a useful overview of the immunological concepts that underpin successful cancer patients' immuno therapies (Figure 4) [8].



Figure 4. Mechanism of action of adoptive transfer infusion.

CHALLENGES AND FUTURE PROGRESS IN IMMUNOTHERAPY

Novel therapy approaches and new insights into the prognosis of cancer have necessitated the use of innovative delivery mechanisms when giving anticancer medications. Currently being researched for a variety of cancer types, immunotherapy-based medications have little effect on solid tumors due to minimal immune cell infiltration, which lowers tumor immunogenicity and creates an immunosuppressive environment within the tumor [6–10]. Treatment of solid tumors might be

possible with the development of novel and distinctive drug delivery methods in conjunction with different cancer therapies. Some of the main obstacles to creating a reliable delivery system are the regulated release of medications at the intended location, methods for evaluating these delivery mechanisms, and their impact on the cellular or molecular level. Through a knowledge of improved permeability and retention, cancer nano medicine-based approaches have made progress in the past thirty years in addressing the tumor microenvironment; nonetheless, there are still significant obstacles to be overcome in the clinically driven transition of developing and approving these treatments [11].

Stability, off-target accumulation, in vitro-to-in vivo correlation, and meeting regulatory requirements for achieving clinical translation are some of the disadvantages of many cancer nano formulations. Large-scale manufacture, physiochemical characterization, creating low-toxicity nano-particles, and meeting regulatory requirements for successful market release are major obstacles in the development of drug delivery systems utilizing nano-particles. Following recent groundbreaking approvals, CAR-T cell therapy has attracted attention. However, in order to increase the efficacy and safety of different forms of cancer, many clinical applications still need to be resolved with improved genome editing and cell engineering technologies. Extracellular vesicles, nanoparticles, scaffolds, and cellular-based vehicles have all shown encouraging results in the delivery of drugs against cancer; however, in order for these treatments to fully combat cancer, further understanding of the mechanisms by which TME effectively infiltrate and evade the immune system is required [12–14].

As 3D printing and tailored delivery digital devices have advanced, so too has the attractiveness of a multi-centric strategy for conducting oncological therapy research employing novel medications and delivery systems. The creation of implantable microchips or nano-robots that can deliver medication and slow the growth of tumors will advance significantly in the future. The development of intelligent nano robotic-based drug carriers for the delivery of nano-medicines will require intelligent and resilient multidisciplinary techniques in the future, where biotechnology and computer-based artificial intelligence should work together. It is imperative to meticulously evaluate their possible effects on animals and the ecosystem prior to granting treatment authorization [9].

CONCLUSION

The progress outlined herein is from a time when William B. Coley first initiated the concept of cancer immunotherapy to this day, through immune checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccines. Coley did the initial experiments with bacterial mixtures that provided a foundation about the immune system's potential in fighting cancer, despite initial setbacks and subsequent adoption of conventional therapies. This discovery, among others, of immune checkpoints – CTLA-4 by Dr. Allison and PD-1 by Dr. Honjo – represented a paradigm shift in the development of new treatments that enhance immune responses against tumors. Today, strategies of immunotherapy are diversified, targeting either different aspects of the immune system or the tumor microenvironment in order to enhance treatment efficacy and safety. Despite this, challenges persist, especially with respect to the optimization of delivery mechanisms, the overcoming of tumor immunosuppression in solid tumors, and the handling of potential toxicities from such novel therapies.

Looking forward, research and innovation conducted to date are very promising in terms of overcoming these challenges in order to broaden the applicability of immunotherapy to a wide range of cancer diseases. We will exploit advancements in technology – such as nano-medicine and genetic engineering – coupled with multidisciplinary expertise, further boosting the outcome and accessibility of treatment for cancer diseases through immunotherapy. From Coley's toxin to modern immunotherapy, the story at bottom is a testament to the potentials for harnessing the power of the

immune system in the fight against cancer and lights up one of the more promising paths ahead for oncological care.

REFERENCES

1. Esfahani K, Roudaia L, Buhlaiga N, Rincon SVD, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(S2):87–97. doi:10.3747/co.27.5223.
2. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–3060. doi:10.3390/curroncol29050247.
3. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The identification of immunological biomarkers in kidney cancers. Front Oncol. 2018;8:456. doi:10.3389/fonc.2018.00456.
4. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7.
5. National Cancer Institute. (2019). Immunotherapy to treat cancer [Online]. Cancer.gov. Available from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy.
6. Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8(1):450. doi:10.1038/s41392-023-01674-3.
7. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308. doi:10.1038/nrc2355.
8. BpsBioscience.com. (2024). Custom CAR T-Cell development services [Online]. Bpsbioscience. Available from: https://bpsbioscience.com/custom-car-t-cell-development.
9. Muthukutty P, Woo HY, Ragothaman M, Yoo SY. Recent advances in cancer immunotherapy delivery modalities. Pharm. 2023:15(2):504. doi:10.3390/pharmaceutics15020504.
10. Liu X, Cheng Y, Mu Y, Zhang Z, Tian D, Liu Y, Hu X, Wen T. Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview. Front Immunol. 2024;15:1328145. doi:10.3389/fimmu.2024.1328145.
11. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration. 2022;2(3):20210106. doi:10.1002/EXP.20210106.
12. Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O'Carroll KF, Li G. Cancer immunotherapy and delivery system: an update. Pharma. 2022;14(8):1630. doi:10.3390/pharmaceutics14081630.
13. Pérez-Herrero E, Lanier OL, Krishnan N, D'Andrea A, Peppas NA. Drug delivery methods for cancer immunotherapy. Drug Deliv Trans Res. 2024;14(1):30–61. doi:10.1007/s13346-023-01405-9.
14. Fan X, Wang K, Lu Q, Lu Y, Sun J. Cell-based drug delivery systems participate in the cancer immunity cycle for improved cancer immunotherapy. Small. 2023;19(4):2205166. doi:10.1002/smll.202205166.

